Collegium Pharmaceutical
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell COLL and other ETFs, options, and stocks.About COLL
Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic.
CEOVikram Karnani
CEOVikram Karnani
Employees357
Employees357
HeadquartersStoughton, Massachusetts
HeadquartersStoughton, Massachusetts
Founded2002
Founded2002
Employees357
Employees357
COLL Key Statistics
Market cap1.44B
Market cap1.44B
Price-Earnings ratio28.34
Price-Earnings ratio28.34
Dividend yield—
Dividend yield—
Average volume453.54K
Average volume453.54K
High today—
High today—
Low today—
Low today—
Open price$46.33
Open price$46.33
Volume0.00
Volume0.00
52 Week high$50.79
52 Week high$50.79
52 Week low$23.23
52 Week low$23.23
Stock Snapshot
With a market cap of 1.44B, Collegium Pharmaceutical(COLL) trades at $45.53. The stock has a price-to-earnings ratio of 28.34.
Collegium Pharmaceutical(COLL) stock opened on 2026-01-05 at $46.33. The price climbed to — and dipped to —.
The Collegium Pharmaceutical(COLL)'s current trading volume is 0, compared to an average daily volume of 453.54K.
In the last year, Collegium Pharmaceutical(COLL) shares hit a 52-week high of $50.79 and a 52-week low of $23.23.
In the last year, Collegium Pharmaceutical(COLL) shares hit a 52-week high of $50.79 and a 52-week low of $23.23.
COLL News
TipRanks 6d
Collegium Pharmaceutical closes $980M syndicated credit facilityCollegium Pharmaceutical (COLL) announced the closing of its inaugural syndicated credit facility. The new aggregate $980M credit facility will mature in 2030 a...
Analyst ratings
83%
of 6 ratingsBuy
83.3%
Hold
16.7%
Sell
0%
People also own
Based on the portfolios of people who own COLL. This list is generated using Robinhood data, and it’s not a recommendation.